New epilepsy drugs that use high doses of antibodies that help the body fight the virus could help patients with epilepsy.
The new drugs, which are being tested in clinical trials in the U.S. and abroad, may be a significant breakthrough in epilepsy treatment.
“This is a very exciting development,” said Dr. Mark T. Johnson, a neuroscientist at Stanford University School of Medicine and a leading proponent of the new treatments.
“These drugs are the first in the series of vaccines for the virus.
They are very promising.
They may help with seizures in the most severe cases.”
The drugs, named Nivivox and Epidiolex, are a combination of antibodies and anti-epileptic drugs.
The antibodies are produced in laboratory mice.
Epidios, a newer antibody drug, is more sensitive.
The vaccines are designed to treat the virus in the brain, and help protect the brain from infection.
The two drugs were developed by a company called EpiPharma.
The drugs are currently being tested by a team at the University of Pennsylvania and the University at Albany in New York.
They were developed as part of the $1.5 billion National Institutes of Health (NIH) program to develop the antibodies.
The first drugs were tested in mice that had a mutation in a gene called BCL-1 that makes antibodies to the virus that protects neurons.
Researchers in the NIH program are now using these antibodies to test a different strain of the virus, called the coronavirus, to see if the antibodies are effective.
This type of vaccine, known as an intramuscular vaccine, works by injecting the antibodies into the bloodstream of a patient.
It’s a process called intradermal injection, which is much easier to administer than a nasal spray.
EpiMedics, which develops the vaccines, said the antibodies work in about 30 minutes in healthy people, while in some people it takes two to three hours.
The goal of this approach is to treat people who are very vulnerable to coronaviruses.
The vaccine also is designed to protect the brains of children.
The virus has killed more than 1.6 million people worldwide, and has been linked to a large number of childhood deaths.
For children, a vaccine that is safe, effective and cost-effective is crucial.
The New York-based company also is working with the FDA to develop an intranasal vaccine that would work with children with severe cases of epilepsy, said Dr.-Ingram R. Johnson.
The intranesal vaccine is likely to be tested in people over the age of three.
The drug’s price will be around $20,000 per dose, and it will be given for about a month before a patient stops getting the antibodies, Johnson said.
The FDA approved the drug, Epidiol, in February for use in people aged 14 and older with moderate-to-severe epilepsy, the agency said.
A company called CVS Therapeutics has also tested the intranisables in adults, the FDA said.
There are other drugs in the pipeline that may be used to treat seizures.
The companies are testing the vaccines in people who have had severe brain infections and are not seizure-free, Johnson told reporters at a news conference Thursday.
The most recent results of trials show that in people under 18, EpiDocs has been associated with a reduction in seizure frequency of about two percent.
There has been a “very significant reduction in seizures” in the trial of the intramisabels, Johnson added.
The next step is to make sure the drugs work in people at higher risk of having seizures, including people who were born with a condition called Lennox-Gastaut syndrome, which affects about 1.4 million people in the United States, Johnson noted.
“There is also evidence that people with this disorder have increased rates of seizure frequency, so we want to do our best to be sure that these drugs are effective and effective in this population.”
EpiTox was developed by CVS.
The company said it was able to improve the results of a study of its drug, Rettetan, in children with a severe form of the illness.
The study showed that Rettotan was effective in a subset of children who were already seizure-prone.
CVS, in a statement, said it plans to work with EpiMeds to make EpiDox and the intrasables available to the general public.
“We are excited about the opportunities that these new treatments present to treat epilepsy in children, and look forward to working with researchers and patients in the field to ensure that these therapies reach their full potential,” CVS said.
About a dozen EpiMedical drug companies are also developing new vaccines, including Takeda Pharmaceuticals Inc., Novartis AG, Novartes, AstraZeneca Plc and Novartine, a division